Terminal Blood Cancers
No options. No hope.
There are currently 1.3 million people living with leukemia, myeloma, and lymphoma in North America. Most are being treated with a combination of drugs and radiation with major side effects. Statistically speaking 60% will survive 5 years. 61,000 die annually. Currently $20 Billion Dollars is Spend fighting terminal blood cancers. There are some that are refractory to all treatments and are left hopeless – we are here to change that.
Now there is hope – DRE-W
Not just another Herbal Remedy
It started in 2009 with a patient of Windsor oncologist Dr. Caroline Hamm who was given only months to live after all conventional therapy for his leukemia had failed. Dr. Hamm recommended that he brew a home-made dandelion root tea that had benefited some of her other patients. Within a few weeks, the patient’s leukemia blast counts were declining and he went into remission. This remarkable story has been featured on CBC.
With funding from government grants and private foundations, Dr. Pandey at the University of Windsor has developed DRE-W, a concentrated freeze-dried extract containing 5 to 10 times the cancer-killing properties of the home-made dandelion root tea consumed by Dr. Hamm’s patient.
Based on Dr. Hamm’s clinical experience and Dr. Pandey’s preclinical studies, Health Canada has now approved a phase I clinical study of DRE-W in 30 patients with cancers of the blood who have failed conventional therapy. The clinical trial will be carried out at the Windsor Regional Cancer Centre with Dr. Hamm being the Principal Investigator.
What is DRE-W?
Windsor Botanical Therapeutics Inc. (WBTI) has developed a ground-breaking natural health product (NHP), called DRE-W at the University of Windsor (UW) in the laboratory of Professor Siyaram Pandey in collaboration with Dr. Caroline Hamm, an oncologist at the WindsorRegional Cancer Centre (WRCC).
DRE-W is an experimental, natural botanical extract which may provide relief and clinical improvement to terminal cancer patients who have no treatment alternatives. A homemade DRE (or dandelion root tea) has already been used by several dozen cancer patients. The anecdotal clinical experience of terminal cancer patients in clinics at the WRCC and scientific data from Dr. Pandey’s lab have been so compelling, that Health Canada (HC) approved a phase I clinical trial of DRE-W in patients with terminal blood cancers. This is the first cancer clinical trial approved by HC for a NHP. The clinical trial is fully funded by private foundations.
DRE-W is produced by a patent pending process and has the potential to become a revolutionary complementary natural therapy for over 662,000 terminal cancer patients in North America who have no treatment alternatives remaining.
DRE-W for clinical studies is being manufactured for WBTI in a Health Canada approved facility. Each batch of DRE-W is quality controlled for its ability to induce cancer cell death (without harming normal cells) and has the potential to help terminal cancer patients at a reasonable cost. More than 30 terminal cancer patients have taken a homemade DRE (or dandelion root tea) and have had subjective and objective improvement in their condition.
Who We Are
A team of proven entrepreneurs and scientists who are passionate about providing hope to those with no hope.
Joseph J.Elliot, Ph.D.
Dr. Elliot is founding President & CEO of Windsor Botanical Therapeutics Inc. a developer and marketer of a breakthrough natural therapy for terminal cancer patients.
He is also Principal at Biopharm Management Inc. (BMI) a Toronto, Canada based firm providing short and long term management services to the biopharmaceutical industry. For the past 27 years Dr. Elliot has been a serial entrepreneur and former venture capitalist.
Dr. Elliot is a hands-on manager with skills and experience in all facets of the biopharmaceutical business including raising capital, financing, licensing, team building, drug development, manufacturing, regulatory affairs (FDA, Health Canada and BfArM). He has broad experience pharmaceuticals, biologicals and vaccines in oncology and infectious diseases.
Through BMI, Dr. Elliot is currently Managing Director of ERC USA, the North American subsidiary of ERC Belgium, a break-through developer of therapeutic cancer vaccines.
in the past 15 years, Dr. Elliot has raised over $30 million for a number of companies in which he played a leading management role including the founding and growing several biotech companies. These include President & CEO of Receptor Therapeutics Inc., President & CEO of LymphoSign Inc., Vice President & General Manager Operations for MDS Proteomics Inc.; Chief Operating Officer for MtDS Ocata Inc.; Interim Chief Operating Officer of Exogen Neurosciences Inc. He is the founding President and Chairman of PhageTech Inc. of Montreal, Quebec which had a successful IPO under the name Targanta Therapeutics Corporation. He was also initial CEO of Cytochroma Inc., (which was subsequently acquired by OPKO in 2013). He is also a past director of Nexia Biotechnologies Inc. of Montreal, Quebec, and BIOSTAR Inc. of Saskatoon, Saskatchewan. From 1996 to 1999 he was a Vice President (Venture Capital) with MDS Capital Corp. specializing in early stage biotechnology investments.
From 1986 to 1996 Dr. Elliot founded and successfully operated several companies, which sold and distributed vaccines and sera in over 100 countries worldwide. Prior to 1986, he held senior technical and international marketing positions with Pharmacia Canada Inc.(now Pfizer) and Connaught Laboratories Inc. (now Sanofi-Pasteur Vaccines). Dr. Elliot received his PhD in Medical Sciences from McMaster University in 1980.
Siyaram Pandey, Ph.D.
CSO, Director Professor UW
Siyaram Pandey is co-founder of Windsor Botanical Therapeutics Inc. and currently a Professor in the Department of Chemistry & Biochemistry at the University of Windsor.
He received his MSc from Banaras Hindu University (1986), Varansi, India and his PhD from Jawaharlal Nehru University/CCMB (1992), New Delhi, India. He did is postdoctoral training at McGill and joined NRC, Ottawa as a research officer (1993-2000). He joined the University of
Jacqueline Shan, Ph.D., D.Sc., ICD.D
President, Afinity Life Sciences Inc.
Member, Board of Directors
Windsor Botanical Therapeutics Inc.
Dr. Shan holds a PhD in Physiology from the University of Alberta and a Doctor of Science in Pharmacology from the Chinese Academy of Medical Sciences/Peking Union Medical College and is certified by the Quantum Shift Program (Executive Business and Entrepreneurship) from the Richard Ivey Business School and holds ICD.D (Institute of Corporate Directors) accreditation.
Heather Pratt, MBA
Executive Director, Research and Innovation
University of Windsor
Heather Pratt is currently the Executive Director, Research and Innovation at the University of Windsor. With over 15 years of experience in progressive research administration, Heather has played a leading role in the development of the University of Windsor’s research enterprise and the expansion of its scope. During her tenure, the University’s research funding levels have nearly doubled and its research mandate has broadened significantly to sustain increasing support for
Managing Partner of Nexus Financial LLC
Eric Sauve is the Managing Partner of Nexus Financial LLC, a consulting firm providing CFO and securities issuance advisory services. Since 1992 Mr. Sauve has been actively involved in founding and managing investment, venture capital, and mining enterprises. Mr. Sauve holds a Bachelor of Arts Degree in Philosophy from the University of British Columbia.
Mr. Sauve was Founder, President, CEO and CFO of Grant Hartford Corporation; a Montana